Alzheimer’s Drug Poses a Dilemma for the F.D.A.

NYT > Top Stories Pam Belluck and Rebecca RobbinsIf the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works. June 05, 2021 at 11:57PM https://ift.tt/2SWS5su